Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium Zirconium Cyclosilicate (SZC) continuation after discharge in CKD patients with hyperkalaemia
NCT05347693Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2022
- Primary completion
- Dec 2024
- Modality
- DNA Intercalators/Alkylators
- Countries
- 6
01
Overview
Phase 4, randomised, open-label trial in Hyperkalemia comparing SZC Arm with Standard of Care Arm (2 arms). Primary endpoint: Occurrence of normokalaemia at 180 days post-discharge. Started Mar 2022; status: completed.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
Hyperkalemia
Beyond the preview
Go deeper on NCT05347693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05347693.